ZURZUVAE can be used to treat many types of patients with postpartum depression (PPD)

Select each profile to see why ZURZUVAE® (zuranolone) may be appropriate for these patient types.

These are hypothetical profiles only. All treatment decisions should be up to the discretion of the HCP and patient,
as each patient’s situation may vary.

Actor portrayals.

“I thought I just had the baby blues and it would get better, but the sadness I felt in the first few weeks didn’t go away”

Patient history and
screening

  • No history of depression or antidepressant use
  • OBGYN nurse practitioner screened for depressive symptoms with EPDS in the first trimester to establish baseline

Symptom presentation

  • Down and disengaged days
    before delivery
  • Felt overwhelmed and had brain fog immediately after delivery, and felt consistent sadness in the weeks after giving birth

PPD diagnosis and
treatment considerations

  • Screening was suggestive of PPD at virtual visit 4 weeks postpartum
  • At in-person follow-up, persistent and worsening symptoms noted and PPD diagnosis made
    • Met DSM-5-TR criteria for PPD, presenting with depressed mood, loss of interest in activities, loss of energy, feelings of guilt, and difficulty concentrating
  • Concerned about being on an antidepressant long-term

DSM-5-TR, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision; EPDS, Edinburgh Postnatal Depression Scale.

DSM-5-TR criteria

Diagnostic criteria for a major depressive episode with peripartum onset3

 
 

Patients must have 5 or more of the following symptoms nearly every day* during the same 2-week period and change from previous functioning. At least 1 symptom must either be depressed mood or loss of interest/pleasure.

 
 
  • Depressed mood most of the day
  • Loss of interest/pleasure in almost all activities most of the day
  • Significant change in weight or appetite
  • Insomnia or hypersomnia
  • Psychomotor agitation/retardation
  • Loss of energy or fatigue
  • Feelings of worthlessness or excessive or inappropriate guilt
  • Difficulty concentrating or indecisiveness
  • Recurrent suicidal thoughts or actions or recurrent thoughts of death
 
 

Additional criteria:

 
 
  • Symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
  • Episode is not attributable to the physiological effects of a substance or to another medical condition
 
 

Peripartum onset specifier:

 
 
  • Symptom onset occurs during pregnancy or within 4 weeks after delivery
 
 

*”Nearly every day” does not apply to weight gain and recurrent suicidal thoughts or actions or recurrent thoughts of death.

 
 

These are not the complete diagnostic criteria for PPD. The criteria listed here are adapted from the DSM-5-TR®. DSM-5® is a registered trademark of the American Psychiatric Association.

Do you see patients like Lina
in your practice?

Take a novel approach to treating PPD
with a 14-day treatment1,2

“I took an antidepressant in the past, but I stopped taking it.
I don’t want to try it again”

Patient history and
screening

  • Took antidepressant previously; not currently on treatment
  • OBGYN screened for depressive symptoms throughout pregnancy; on high alert for symptoms during the third trimester and after delivery

Symptom presentation

  • Depressed, tired, and irritable
    a few weeks after delivery
  • Worried about symptoms impacting her life

PPD diagnosis and
treatment considerations

  • At 6-week appointment, admitted to “toughing it out” despite worsening symptoms
  • OBGYN nurse practitioner assessed Ava and diagnosed her with PPD
    • Met DSM-5-TR criteria for PPD, presenting with depressed mood, insomnia, psychomotor agitation, fatigue, feelings of worthlessness, and indecisiveness
  • Hesitant about taking her prior antidepressant again
DSM-5-TR criteria

Diagnostic criteria for a major depressive episode with peripartum onset3

 
 

Patients must have 5 or more of the following symptoms nearly every day* during the same 2-week period and change from previous functioning. At least 1 symptom must either be depressed mood or loss of interest/pleasure.

 
 
  • Depressed mood most of the day
  • Loss of interest/pleasure in almost all activities most of the day
  • Significant change in weight or appetite
  • Insomnia or hypersomnia
  • Psychomotor agitation/retardation
  • Loss of energy or fatigue
  • Feelings of worthlessness or excessive or inappropriate guilt
  • Difficulty concentrating or indecisiveness
  • Recurrent suicidal thoughts or actions or recurrent thoughts of death
 
 

Additional criteria:

 
 
  • Symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
  • Episode is not attributable to the physiological effects of a substance or to another medical condition
 
 

Peripartum onset specifier:

 
 
  • Symptom onset occurs during pregnancy or within 4 weeks after delivery
 
 

*”Nearly every day” does not apply to weight gain and recurrent suicidal thoughts or actions or recurrent thoughts of death.

 
 

These are not the complete diagnostic criteria for PPD. The criteria listed here are adapted from the DSM-5-TR®. DSM-5® is a registered trademark of the American Psychiatric Association.

Do you see patients like Ava
in your practice?

Take a novel approach to treating PPD
with a 14-day treatment1,2

“I have no energy these days and I can’t seem to focus or make decisions.
I’m nervous to go back to work soon”

Patient history and
screening

  • Prescribed antidepressant prior to pregnancy, which she continued throughout
  • Screened for depressive symptoms throughout pregnancy

Symptom presentation

  • New symptoms of depressed
    mood and feeling worthless
  • Felt anxious about her ability to care for her newborn, which also impacted her sleep
  • Worried about returning to work soon after new symptoms started several weeks ago

PPD diagnosis and
treatment considerations

  • At 6-week appointment, OBGYN assessed Kiera and diagnosed her with PPD
    • Met DSM-5-TR criteria for PPD, presenting with depressed mood, significant change in weight, insomnia, fatigue, feelings of worthlessness, and difficulty concentrating
  • Discussed treatment options that could be used with her current antidepressant
DSM-5-TR criteria

Diagnostic criteria for a major depressive episode with peripartum onset3

 
 

Patients must have 5 or more of the following symptoms nearly every day* during the same 2-week period and change from previous functioning. At least 1 symptom must either be depressed mood or loss of interest/pleasure.

 
 
  • Depressed mood most of the day
  • Loss of interest/pleasure in almost all activities most of the day
  • Significant change in weight or appetite
  • Insomnia or hypersomnia
  • Psychomotor agitation/retardation
  • Loss of energy or fatigue
  • Feelings of worthlessness or excessive or inappropriate guilt
  • Difficulty concentrating or indecisiveness
  • Recurrent suicidal thoughts or actions or recurrent thoughts of death
 
 

Additional criteria:

 
 
  • Symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
  • Episode is not attributable to the physiological effects of a substance or to another medical condition
 
 

Peripartum onset specifier:

 
 
  • Symptom onset occurs during pregnancy or within 4 weeks after delivery
 
 

*”Nearly every day” does not apply to weight gain and recurrent suicidal thoughts or actions or recurrent thoughts of death.

 
 

These are not the complete diagnostic criteria for PPD. The criteria listed here are adapted from the DSM-5-TR®. DSM-5® is a registered trademark of the American Psychiatric Association.

Do you see patients like Kiera
in your practice?

Take a novel approach to treating PPD
with a 14-day treatment1,2

Learn about the 3 steps needed to start your patients with PPD on ZURZUVAE

How to get patients started

Discover how quickly ZURZUVAE delivered symptom relief

See efficacy results

References: 1. ZURZUVAE Prescribing Information. Cambridge, MA: Biogen and Sage Therapeutics, Inc. 2. Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. Zuranolone for the Treatment of Postpartum Depression. Am J Psych. 2023;180(9):668-675. 3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, Text Revision. American Psychiatric Publishing; 2022.